Can a patient with a history of pulmonary embolism, a creatinine clearance of about 125 mL/min and a body weight of 138 kg, take edoxaban for secondary prevention?

Can he take edoxaban for history of PE?

Yes, edoxaban is an appropriate and effective option for secondary prevention of pulmonary embolism in this patient, but the standard 60 mg daily dose should be used given his creatinine clearance of 125 mL/min and body weight of 138 kg.

Edoxaban for VTE Treatment and Secondary Prevention

Edoxaban is a validated treatment option for pulmonary embolism with strong guideline support. The 2020 ESC guidelines recommend preferring a NOAC (including edoxaban) over warfarin when initiating oral anticoagulation in patients with PE who are eligible 1. The 2022 ITAC guidelines similarly endorse edoxaban as a first-line option for established VTE treatment in cancer patients with creatinine clearance ≥30 mL/min 2.

The landmark Hokusai-VTE trial demonstrated that edoxaban was noninferior to warfarin for preventing recurrent symptomatic VTE (3.2% vs 3.5%, HR 0.89) and caused significantly less bleeding (8.5% vs 10.3%, HR 0.81) 3. This included patients with severe pulmonary embolism.

Critical Dosing Considerations for This Patient

Standard Dose Required

This patient requires the standard 60 mg daily dose of edoxaban, NOT a reduced dose. The dose reduction criteria are specific 4, 5:

• Reduce to 30 mg daily ONLY if:
  • Creatinine clearance 30-50 mL/min, OR
  • Body weight <60 kg, OR
  • Concomitant potent P-glycoprotein inhibitors

This patient meets NONE of these criteria:

• CrCl 125 mL/min (well above 50 mL/min threshold)
• Weight 138 kg (far above 60 kg threshold)

High Creatinine Clearance Caveat

Important consideration: While edoxaban is approved for VTE treatment across the renal function spectrum, there is a specific FDA restriction for atrial fibrillation patients with CrCl >95 mL/min due to reduced efficacy in that population 6, 7. However, this restriction does NOT apply to VTE treatment - it only applies to stroke prevention in atrial fibrillation 1.

For VTE treatment specifically, edoxaban maintains efficacy even at higher creatinine clearance levels. The Hokusai-VTE trial included patients across the renal function spectrum and demonstrated consistent efficacy 3.

Treatment Protocol

Edoxaban requires initial parenteral anticoagulation before starting oral therapy 4, 5, 2:

1. Initial phase (minimum 5 days): LMWH or UFH

   • Dalteparin 200 units/kg SC daily, OR
   • Enoxaparin 1 mg/kg SC every 12 hours

2. After ≥5 days of parenteral therapy: Switch to edoxaban 60 mg once daily

3. Duration: Minimum 3 months for provoked PE; indefinite for unprovoked or recurrent VTE 1, 8

Advantages Over Alternatives

• No INR monitoring required (unlike warfarin)
• Once-daily dosing (simpler than twice-daily apixaban)
• Lower bleeding risk than warfarin with equivalent efficacy 3
• No initial parenteral overlap needed once the 5-day lead-in is complete

Common Pitfalls to Avoid

1. Do NOT use 30 mg dose - this patient's high weight and excellent renal function require standard dosing
2. Do NOT skip the initial 5-day parenteral anticoagulation - edoxaban cannot be started immediately like rivaroxaban or apixaban
3. Do NOT confuse atrial fibrillation dosing restrictions with VTE treatment - the CrCl >95 mL/min concern applies only to AF, not PE 6
4. Reassess duration at 3 months - if this was unprovoked PE, consider indefinite anticoagulation 1

4, 5, 2, 1, 8, 6, 3